Journal of Clinical Oncology, Vol 18, Issue 4
(February), 2000: 927
© 2000 American Society for Clinical Oncology
Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer
By J. Zujewski,
I. D. Horak,
C. J. Bol,
R. Woestenborghs,
C. Bowden,
D. W. End,
V. K. Piotrovsky,
J. Chiao,
R. T. Belly,
A. Todd,
W. C. Kopp,
D. R. Kohler,
C. Chow,
M. Noone,
F. T. Hakim,
G. Larkin,
R. E. Gress,
R. B. Nussenblatt,
A. B. Kremer,
K. H. Cowan
From the Medicine Branch, Division of Clinical Sciences, National Cancer Institute; Clinical Center, National Institutes of Health; and National Eye Institute, Bethesda; SAIC-Frederick, Frederick, MD; Janssen Research Institute, Titusville, NJ; Janssen Research Foundation, Beerse, Belgium; Ortho-Clinical Diagnostics, Rochester, NY; and Johnson and Johnson Research, Sydney, Australia.
Address reprint requests to Jo Anne Zujewski, MD, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD; email zujewski{at}nih.gov
PURPOSE: To determine the maximum-tolerated dose, toxicities, and pharmacokinetic profile of the farnesyl protein transferase inhibitor R115777 when administered orally bid for 5 days every 2 weeks.
PATIENTS AND METHODS: Twenty-seven patients with a median age of 58 years received 85 cycles of R115777 using an intrapatient and interpatient dose escalation schema. Drug was administered orally at escalating doses as a solution (25 to 850 mg bid) or as pellet capsules (500 to 1300 mg bid). Pharmacokinetics were assessed after the first dose and the last dose administered during cycle 1.
RESULTS: Dose-limiting toxicity of grade 3 neuropathy was observed in one patient and grade 2 fatigue (decrease in two performance status levels) was seen in four of six patients treated with 1,300 mg bid. The most frequent clinical grade 2 or 3 adverse events in any cycle included nausea, vomiting, headache, fatigue, anemia, and hypotension. Myelosuppression was mild and infrequent. Peak plasma concentrations of R115777 were achieved within 0.5 to 4 hours after oral drug administration. The elimination of R115777 from plasma was biphasic, with sequential half-lives of about 5 hours and 16 hours. There was little drug accumulation after bid dosing, and steady-state concentrations were achieved within 2 to 3 days. The pharmacokinetics were dose proportional in the 25 to 325 mg/dose range for the oral solution. Urinary excretion of unchanged R115777 was less than 0.1% of the oral dose. One patient with metastatic colon cancer treated at the 500-mg bid dose had a 46% decrease in carcinoembryonic antigen levels, improvement in cough, and radiographically stable disease for 5 months.
CONCLUSION: R115777 is bioavailable after oral administration and has an acceptable toxicity profile. Based upon pharmacokinetic data, the recommended dose for phase II trials is 500 mg orally bid (total daily dose, 1,000 mg) for 5 consecutive days followed by 9 days of rest. Studies of continuous dosing and studies of R115777 in combination with chemotherapy are ongoing.
The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organization imply endorsement by the United States government.
This article has been cited by other articles:
|
|
|
|
 
S. A. Danovi, H. H. Wong, and N. R. Lemoine
Targeted therapies for pancreatic cancer
Br. Med. Bull.,
September 1, 2008;
87(1):
97 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Haas-Kogan, A. Banerjee, M. Kocak, M. D. Prados, J. R. Geyer, M. Fouladi, T. McKnight, T. Y. Poussaint, A. Broniscer, S. M. Blaney, et al.
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma
Neuro-oncol,
January 1, 2008;
10(3):
341 - 347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Qiu, X. Liu, W. Zou, P. Yue, S. Lonial, F. R. Khuri, and S.-Y. Sun
The Farnesyltransferase Inhibitor R115777 Up-regulates the Expression of Death Receptor 5 and Enhances TRAIL-Induced Apoptosis in Human Lung Cancer Cells
Cancer Res.,
May 15, 2007;
67(10):
4973 - 4980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L Gore, S. Holden, R. Cohen, M Morrow, A. Pierson, C. O'Bryant, M Persky, D Gustafson, C Mikule, S Zhang, et al.
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors
Ann. Onc.,
November 1, 2006;
17(11):
1709 - 1717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Siegel-Lakhai, M. Crul, P. De Porre, S. Zhang, I. Chang, H. Boot, J. H. Beijnen, and J. H.M. Schellens
Clinical and Pharmacologic Study of the Farnesyltransferase Inhibitor Tipifarnib in Cancer Patients With Normal or Mildly or Moderately Impaired Hepatic Function
J. Clin. Oncol.,
October 1, 2006;
24(28):
4558 - 4564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Zhang, P. Zannikos, A. Awada, M. Piccart-Gebhart, L. Y. Dirix, P. Fumoleau, T. Verhaeghe, M. Francois, and P. De Porre
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer.
J. Clin. Pharmacol.,
October 1, 2006;
46(10):
1116 - 1127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. F. Cloughesy, P. Y. Wen, H. I. Robins, S. M. Chang, M. D. Groves, K. L. Fink, L. Junck, D. Schiff, L. Abrey, M. R. Gilbert, et al.
Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
J. Clin. Oncol.,
August 1, 2006;
24(22):
3651 - 3656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Sparano, S. Moulder, A. Kazi, L. Vahdat, T. Li, C. Pellegrino, P. Munster, M. Malafa, D. Lee, S. Hoschander, et al.
Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide
J. Clin. Oncol.,
July 1, 2006;
24(19):
3013 - 3018.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. C. Widemann, W. L. Salzer, R. J. Arceci, S. M. Blaney, E. Fox, D. End, A. Gillespie, P. Whitcomb, J. S. Palumbo, A. Pitney, et al.
Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas
J. Clin. Oncol.,
January 20, 2006;
24(3):
507 - 516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Basso, P. Kirschmeier, and W. R. Bishop
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors
J. Lipid Res.,
January 1, 2006;
47(1):
15 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. F. Cloughesy, J. Kuhn, H. I. Robins, L. Abrey, P. Wen, K. Fink, F. S. Lieberman, M. Mehta, S. Chang, A. Yung, et al.
Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
J. Clin. Oncol.,
September 20, 2005;
23(27):
6647 - 6656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M.G.M. Appels, J. H. Beijnen, and J. H.M. Schellens
Development of Farnesyl Transferase Inhibitors: A Review
Oncologist,
September 1, 2005;
10(8):
565 - 578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Larghero, N. Gervais, B. Cassinat, J.-D. Rain, M.-H. Schlageter, R. A. Padua, C. Chomienne, and P. Rousselot
Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells
Blood,
May 1, 2005;
105(9):
3743 - 3745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Ferguson, L. E. Rodriguez, J. P. Palma, M. Refici, K. Jarvis, J. O'Connor, G. M. Sullivan, D. Frost, K. Marsh, J. Bauch, et al.
Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models
Clin. Cancer Res.,
April 15, 2005;
11(8):
3045 - 3054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. F. Lebowitz, J. Eng-Wong, B. C. Widemann, F. M. Balis, N. Jayaprakash, C. Chow, G. Clark, S. B. Gantz, D. Venzon, and J. Zujewski
A Phase I Trial and Pharmacokinetic Study of Tipifarnib, a Farnesyltransferase Inhibitor, and Tamoxifen in Metastatic Breast Cancer
Clin. Cancer Res.,
February 1, 2005;
11(3):
1247 - 1252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Zimmerman, H. Harlin, O. M. Odenike, S. Berk, E. Sprague, T. Karrison, W. Stock, R. A. Larson, M. J. Ratain, and T. F. Gajewski
Dose-Ranging Pharmacodynamic Study of Tipifarnib (R115777) in Patients With Relapsed and Refractory Hematologic Malignancies
J. Clin. Oncol.,
December 1, 2004;
22(23):
4816 - 4822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Moulder, J. J. Mahany, R. Lush, C. Rocha-Lima, M. Langevin, K. J. Ferrante, L. M. Bartkowski, S. M. Kajiji, D. A. Noe, S. Paillet, et al.
A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors
Clin. Cancer Res.,
November 1, 2004;
10(21):
7127 - 7135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rao, D. Cunningham, A. de Gramont, W. Scheithauer, M. Smakal, Y. Humblet, G. Kourteva, T. Iveson, T. Andre, J. Dostalova, et al.
Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer
J. Clin. Oncol.,
October 1, 2004;
22(19):
3950 - 3957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Heymach, D. H. Johnson, F. R. Khuri, H. Safran, L. L. Schlabach, F. Yunus, R. F. DeVore III, P. M. De Porre, H. M. Richards, X. Jia, et al.
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer
Ann. Onc.,
August 1, 2004;
15(8):
1187 - 1193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R. Parulekar and E. A. Eisenhauer
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
J Natl Cancer Inst,
July 7, 2004;
96(13):
990 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Mo and C. E. Elson
Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention
Experimental Biology and Medicine,
July 1, 2004;
229(7):
567 - 585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Khuri, B. S. Glisson, E. S. Kim, P. Statkevich, P. F. Thall, M. L. Meyers, R. S. Herbst, R. F. Munden, C. Tendler, Y. Zhu, et al.
Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors
Clin. Cancer Res.,
May 1, 2004;
10(9):
2968 - 2976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Van Cutsem, H. van de Velde, P. Karasek, H. Oettle, W.L. Vervenne, A. Szawlowski, P. Schoffski, S. Post, C. Verslype, H. Neumann, et al.
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
J. Clin. Oncol.,
April 15, 2004;
22(8):
1430 - 1438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Ryan, J. P. Eder Jr., T. Puchlaski, M. V. Seiden, T. J. Lynch, C. S. Fuchs, P. C. Amrein, D. Sonnichsen, J. G. Supko, and J. W. Clark
Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors
Clin. Cancer Res.,
April 1, 2004;
10(7):
2222 - 2230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Sebti
Blocked Pathways: FTIs Shut Down Oncogene Signals
Oncologist,
December 1, 2003;
8(90003):
30 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ochiai, R. Uchida, S.-i. Fuchida, A. Okano, M. Okamoto, E. Ashihara, T. Inaba, N. Fujita, H. Matsubara, and C. Shimazaki
Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro
Blood,
November 1, 2003;
102(9):
3349 - 3353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Patnaik, S. G. Eckhardt, E. Izbicka, A. A. Tolcher, L. A. Hammond, C. H. Takimoto, G. Schwartz, H. McCreery, A. Goetz, M. Mori, et al.
A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies
Clin. Cancer Res.,
October 15, 2003;
9(13):
4761 - 4771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu
Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents
J. Clin. Oncol.,
July 15, 2003;
21(14):
2760 - 2776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R.D. Johnston, T. Hickish, P. Ellis, S. Houston, L. Kelland, M. Dowsett, J. Salter, B. Michiels, J. J. Perez-Ruixo, P. Palmer, et al.
Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer
J. Clin. Oncol.,
July 1, 2003;
21(13):
2492 - 2499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Adjei, A. Mauer, L. Bruzek, R. S. Marks, S. Hillman, S. Geyer, L. J. Hanson, J. J. Wright, C. Erlichman, S. H. Kaufmann, et al.
Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
May 1, 2003;
21(9):
1760 - 1766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Cohen, L. Ho, S. Ranganathan, J. L. Abbruzzese, R. K. Alpaugh, M. Beard, N. L. Lewis, S. McLaughlin, A. Rogatko, J. J. Perez-Ruixo, et al.
Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
J. Clin. Oncol.,
April 1, 2003;
21(7):
1301 - 1306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. G. El Kamar, M. L. Grossbard, and P. S. Kozuch
Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative Care
Oncologist,
February 1, 2003;
8(1):
18 - 34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Korf
Review Article : Determination of End Points for Treatment of Neurofibromatosis 1
J Child Neurol,
August 1, 2002;
17(8):
642 - 645.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Crul, G. J. de Klerk, M. Swart, L. J. van't Veer, D. de Jong, L. Boerrigter, P. A. Palmer, C. J. Bol, H. Tan, G. C. de Gast, et al.
Phase I Clinical and Pharmacologic Study of Chronic Oral Administration of the Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer
J. Clin. Oncol.,
June 1, 2002;
20(11):
2726 - 2735.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Smith, M. G. Rowlands, E. Barrie, P. Workman, and L. R. Kelland
Establishment and Characterization of Acquired Resistance to the Farnesyl Protein Transferase Inhibitor R115777 in a Human Colon Cancer Cell Line
Clin. Cancer Res.,
June 1, 2002;
8(6):
2002 - 2009.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Britten, E. K. Rowinsky, S. Soignet, A. Patnaik, S.-L. Yao, P. Deutsch, Y. Lee, R. B. Lobell, K. E. Mazina, H. McCreery, et al.
A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Malignancies
Clin. Cancer Res.,
December 1, 2001;
7(12):
3894 - 3903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Kelland, V. Smith, M. Valenti, L. Patterson, P. A. Clarke, S. Detre, D. End, A. J. Howes, M. Dowsett, P. Workman, et al.
Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer
Clin. Cancer Res.,
November 1, 2001;
7(11):
3544 - 3550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ottoboni, A. Crippa, C. Falugi, and P. Russo
Induction of micronuclei by a new non-peptidic mimetic farnesyltransferase inhibitor RPR-115135: role of gene mutations
Mutagenesis,
September 1, 2001;
16(5):
423 - 430.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Adjei
Blocking Oncogenic Ras Signaling for Cancer Therapy
J Natl Cancer Inst,
July 18, 2001;
93(14):
1062 - 1074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, J. E. Lancet, S. H. Kaufmann, D. W. End, J. J. Wright, K. Bol, I. Horak, M. L. Tidwell, J. Liesveld, T. J. Kottke, et al.
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
Blood,
June 1, 2001;
97(11):
3361 - 3369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Tolcher
Novel Compounds in the Therapy of Breast Cancer: Opportunities for Integration with Docetaxel
Oncologist,
June 1, 2001;
6(2008):
40 - 44.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Morgan, O. Dolp, and C. W. M. Reuter
Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling
Blood,
March 15, 2001;
97(6):
1823 - 1834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. A.L.M. Eskens, A. Awada, D. L. Cutler, M. J.A. de Jonge, G. P.M. Luyten, M. N. Faber, P. Statkevich, A. Sparreboom, J. Verweij, A.-R. Hanauske, et al.
Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors
J. Clin. Oncol.,
February 15, 2001;
19(4):
1167 - 1175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Korf
Malignancy in Neurofibromatosis Type 1
Oncologist,
December 1, 2000;
5(6):
477 - 485.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Sharma and L. B. Saltz
Oral Chemotherapeutic Agents for Colorectal Cancer
Oncologist,
April 1, 2000;
5(2):
99 - 107.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. R. Ashar, L. James, K. Gray, D. Carr, S. Black, L. Armstrong, W. R. Bishop, and P. Kirschmeier
Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules
J. Biol. Chem.,
September 22, 2000;
275(39):
30451 - 30457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
